UBS upgraded 3M from Neutral to Buy and set a new price target of $184.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/22/2025 | $140.00 → $170.00 | Equal Weight → Overweight | Wells Fargo |
| 11/13/2024 | $184.00 | Neutral → Buy | UBS |
| 10/22/2024 | Hold → Buy | Melius | |
| 9/6/2024 | $125.00 | Underweight | Morgan Stanley |
| 7/30/2024 | $145.00 | Hold → Buy | Argus |
| 7/29/2024 | $110.00 → $150.00 | Hold → Buy | Deutsche Bank |
| 6/13/2024 | $125.00 | Peer Perform → Outperform | Wolfe Research |
| 6/7/2024 | $105.00 → $120.00 | Neutral → Buy | BofA Securities |
For Immediate Release: January 22, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The FDA’s Office of Criminal Investigations recently investigated a case that has led to an arrest and the filing of a criminal complaint by the U.S. Department of Justice for introducing misbranded drugs into interstate commerce. The criminal investigation found th